JPH07178131A - Traumatoprotective covering material - Google Patents
Traumatoprotective covering materialInfo
- Publication number
- JPH07178131A JPH07178131A JP5324153A JP32415393A JPH07178131A JP H07178131 A JPH07178131 A JP H07178131A JP 5324153 A JP5324153 A JP 5324153A JP 32415393 A JP32415393 A JP 32415393A JP H07178131 A JPH07178131 A JP H07178131A
- Authority
- JP
- Japan
- Prior art keywords
- wound
- contact layer
- support layer
- collagen
- reinforcing material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title abstract description 17
- 239000012779 reinforcing material Substances 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 abstract description 25
- 108010035532 Collagen Proteins 0.000 abstract description 24
- 102000008186 Collagen Human genes 0.000 abstract description 24
- 239000011159 matrix material Substances 0.000 abstract description 16
- 239000004744 fabric Substances 0.000 abstract description 8
- 229920001296 polysiloxane Polymers 0.000 abstract description 7
- 239000000835 fiber Substances 0.000 abstract description 6
- 229920000098 polyolefin Polymers 0.000 abstract description 6
- 229920002635 polyurethane Polymers 0.000 abstract description 6
- 239000004814 polyurethane Substances 0.000 abstract description 6
- 239000004677 Nylon Substances 0.000 abstract description 5
- 229920001778 nylon Polymers 0.000 abstract description 5
- 229920000728 polyester Polymers 0.000 abstract description 5
- 229920002101 Chitin Polymers 0.000 abstract description 4
- 229920000742 Cotton Polymers 0.000 abstract description 4
- 229920000642 polymer Polymers 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 229920004934 Dacron® Polymers 0.000 abstract 1
- 241000208202 Linaceae Species 0.000 abstract 1
- 235000004431 Linum usitatissimum Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000005020 polyethylene terephthalate Substances 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 74
- 208000027418 Wounds and injury Diseases 0.000 description 74
- 230000035876 healing Effects 0.000 description 10
- 108010045569 atelocollagen Proteins 0.000 description 7
- 230000004709 cell invasion Effects 0.000 description 6
- 210000000416 exudates and transudate Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000003176 fibrotic effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002174 Styrene-butadiene Substances 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000012237 artificial material Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229920006268 silicone film Polymers 0.000 description 2
- 239000011115 styrene butadiene Substances 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、創傷面に貼付され、創
面を保護し、自己組織の再生を促すための創傷被覆材に
関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a wound dressing which is applied to a wound surface to protect the wound surface and promote regeneration of self-tissue.
【０００２】[0002]
【従来の技術】熱傷、外傷、手術創などの創傷部分を保
護し治癒を促進するために、患部に一時的に適用される
創傷被覆材として、従来はガーゼ、脱脂綿等が用いられ
たが、これらは感染防止能力が低く、かつ滲出液を吸収
してしまうため創の乾燥固着してしまい、剥すときに出
血、痛み、治癒阻害を伴った。また、軟膏等を併用する
こともあるが、この場合は逆に滲出液の貯留、創面の過
度の湿潤が問題となっている。これらに代わるものとし
て、シリコーン性ガーゼ、 シリコーンゴム製およびベ
ロアー状の表面を有するナイロン、テフロンなどの合成
繊維シート等の人工材料被覆膜や、凍結乾燥豚皮、キチ
ン膜、コラーゲン膜、ポリロンシン膜など生体由来材料
が知られている。2. Description of the Related Art Gauze, absorbent cotton, etc. have been conventionally used as a wound dressing material that is temporarily applied to an affected area in order to protect the wound area such as burns, trauma and surgical wounds and promote healing. These had low infection-preventing ability and absorbed the exudate, so that the wound became dry and fixed, and when it was peeled off, bleeding, pain, and inhibition of healing were accompanied. In addition, an ointment or the like may be used in combination, but in this case, on the contrary, storage of exudate and excessive wetting of the wound surface pose problems. As an alternative to these, artificial material coating films such as silicone gauze, silicone rubber and synthetic fiber sheets such as nylon and Teflon having a velour-like surface, freeze-dried pig skin, chitin film, collagen film, polyloncine film. Bio-derived materials are known.
【０００３】しかし、人工材料は、患部との密着性、生
体適合性、固着防止効果等で問題があり、一方生体由来
材料では、抗原性、創面での融解、感染、滲出液による
劣化がみられる。また、コラーゲン処理されたナイロン
メッシュとシリコーン膜からなる被覆材が開発され、創
面の密着性、適度な水分透過を有するが、創面への固着
が強く、創面の治癒を遅らせるという欠点があった。さ
らにコラーゲンをスポンジ状に加工したものでは、ムコ
多糖含有コラーゲン膜などがあるが、生体内での強度を
保つために化学架橋処理を行っているが、このために異
物性が高くなり治癒を遅らせ、かつ強度的に弱いため手
術時の操作性が悪かった。[0003] However, artificial materials have problems such as adhesion to the affected area, biocompatibility, anti-sticking effect, etc. On the other hand, bio-derived materials have antigenicity, melting on the wound surface, infection, and deterioration due to exudate. To be In addition, a covering material composed of a collagen-treated nylon mesh and a silicone film has been developed, and although it has adhesiveness to the wound surface and appropriate water permeation, it has a drawback that it strongly adheres to the wound surface and delays healing of the wound surface. Furthermore, in the case of collagen processed into a sponge, there is a mucopolysaccharide-containing collagen film, etc., but chemical cross-linking treatment is performed to maintain the strength in vivo, but this increases the foreign substance and delays healing. Moreover, since the strength was weak, the operability during surgery was poor.
【０００４】[0004]
【発明が解決しようとする課題】従来の創傷被覆材は、
それぞれ難点を有しているため、それぞれ有用と思われ
る創の種別に使用されている。前述のように、コラーゲ
ンスポンジ型被覆材では、細胞や血管の侵入による自己
組織化の速度が問題となるが、化学架橋型のスポンジで
は細胞侵入のための適度な孔径のスポンジ構造とその構
造の使用時圧迫に対する維持が問題となってくる。The conventional wound dressings are
Because each has its own drawbacks, it is used for each type of wound that seems useful. As described above, in the collagen sponge type coating material, the rate of self-assembly due to the invasion of cells and blood vessels becomes a problem, but in the chemically crosslinked sponge, the sponge structure with an appropriate pore size for cell invasion and its structure are formed. Maintaining pressure during use becomes a problem.
【０００５】たとえば、生分解性ポリエステルを分散さ
せスポンジ構造を維持したり、凍結乾燥時の温度を変え
ることによりスポンジ孔径を制御して細胞侵入性を維持
しようとしているが、異物性の増加や材料自体の強度不
足から十分な効果は得られていない。このため外部から
の圧迫によるスポンジ構造の破壊のための細胞・血管侵
入性の低下、強度が弱く使用時の操作性が悪いこと、ま
た強度がないための固定のしにくさなどを解決すること
が望まれている。For example, biodegradable polyesters are dispersed to maintain the sponge structure, or the temperature at the time of freeze-drying is changed to control the pore diameter of the sponge to maintain the cell invasion property. Sufficient effect has not been obtained due to its lack of strength. For this reason, it is necessary to solve the problems such as a decrease in cell / vascular invasion due to the destruction of the sponge structure due to external pressure, weak strength and poor operability during use, and difficulty in fixing due to lack of strength. Is desired.
【０００６】[0006]
【課題を解決するための手段】上記の目的は下記の構成
を有する創傷被覆材によって達成される。 （１）創傷部接触層とその上に重層された支持層からな
る創傷被覆材において、前記創傷部接触層および／また
は支持層が繊維状の補強材により補強された創傷被覆
材。 （２）創傷部接触層とその上に重層された支持層からな
り、前記創傷部接触層は、線維化アテロコラーゲンとヘ
リックス含量が０〜８０％である変性コラーゲンとから
なるマトリックスからなり、前記創傷部接触層および／
または支持層が繊維状の補強材により補強された上記
（１）記載の創傷被覆材。The above object is achieved by a wound dressing having the following constitution. (1) A wound dressing comprising a wound contact layer and a support layer laminated thereon, wherein the wound contact layer and / or the support layer is reinforced with a fibrous reinforcing material. (2) The wound contact layer comprises a wound contact layer and a support layer laminated thereon, and the wound contact layer comprises a matrix composed of fibrotic atelocollagen and denatured collagen having a helix content of 0 to 80%. Contact layer and /
Alternatively, the wound dressing according to (1) above, wherein the support layer is reinforced with a fibrous reinforcing material.
【０００７】（３）前記支持層が、シリコーン、ポリウ
レタン、ポリオレフィン、スチレンーブタジエンブロッ
クポリマーおよびポリテトラフルロエチレンのうち少な
くとも１つを含む上記（１）及び（２）記載の創傷被覆
材。 （４）前記繊維状の補強材がポリエステル、ポリウレタ
ン、ナイロン、テトロン、ポリオレフィンなどの合成高
分子もしくは絹、綿、麻、キチンなどの天然由来物質の
不織布、織布もしくは編布からなる上記（１）及び
（２）記載の創傷被覆材。(3) The wound dressing according to the above (1) or (2), wherein the support layer contains at least one of silicone, polyurethane, polyolefin, styrene-butadiene block polymer and polytetrafluoroethylene. (4) The fibrous reinforcing material is composed of a synthetic polymer such as polyester, polyurethane, nylon, tetron, or polyolefin, or a non-woven fabric, woven fabric, or knitted fabric of a naturally derived substance such as silk, cotton, hemp, or chitin. ) And the wound dressing according to (2).
【０００８】（５）前記創傷部接触層に、生理活性物質
が配合されている上記（１）及び（２）記載の創傷被覆
材。 （６）ドレイン用の連通孔が設けられている上記（１）
及び（２）記載の創傷被覆材。(5) The wound dressing material according to the above (1) or (2), wherein a physiologically active substance is blended in the wound contact layer. (6) The above (1) in which a communication hole for drain is provided.
And the wound dressing according to (2).
【０００９】本発明の創傷被覆材は、上記のように、創
傷部接触層とその上に重層された支持層からなり、前記
創傷部接触層および／または支持層が繊維状の補強材に
より補強されてなる。創傷部接触層は、熱傷、外傷、手
術創などの創傷面を直接覆ってこれを柔らかく保護し、
痛みを抑え、適度の水分を与え、細菌の感染を防止す
る。さらに創傷部接触層は、創傷面に適用された極めて
初期にマクロファージや好中球他の炎症性の細胞が浸潤
した後、早期に線維芽細胞と毛細血管系がびまん性に侵
入し、その結果真皮様の結合組織が構築され創傷面の治
癒が促進される。創傷部接触層の真上には、周囲健常表
皮が伸展増殖し、最終的にはその上の支持層は分界・排
除される。As described above, the wound dressing material of the present invention comprises the wound contact layer and the support layer laminated thereon, and the wound contact layer and / or the support layer is reinforced by a fibrous reinforcing material. It will be done. The wound contact layer directly covers the wound surface of burns, trauma, surgical wounds, etc. to protect it softly,
It controls pain, gives moderate amount of water, and prevents bacterial infection. Furthermore, the wound contact layer infiltrates macrophages, neutrophils, and other inflammatory cells very early in the application to the wound surface, and then diffuses fibroblasts and capillaries diffusely, resulting in early infiltration. A dermis-like connective tissue is constructed to promote healing of the wound surface. Immediately above the wound contact layer, the surrounding healthy epidermis extends and proliferates, and finally the supporting layer thereon is demarcated and eliminated.
【００１０】本発明の創傷被覆材において、創傷部接触
層は主としてコラーゲンマトリックスからなる。コラー
ゲンマトリックスとしては、特に限定されないが、線維
化アテロコラーゲンとヘリックス含量が０〜８０％であ
る変性コラーゲンとからなるマトリックスが好ましい。
本発明において支持層は、特に限定されないが、シリコ
ーン、ポリウレタン、ポリオレフィン、スチレンーブタ
ジエンブロックポリマーおよびポリテトラフルロエチレ
ンを単独もしくは少なくとも１つの成分として含むもの
が挙げられ、特にシリコーン製の膜が好ましく用いら
れ、多孔体に成形されていることが好ましい。In the wound dressing of the present invention, the wound contact layer mainly comprises a collagen matrix. The collagen matrix is not particularly limited, but a matrix composed of fibrotic atelocollagen and denatured collagen having a helix content of 0 to 80% is preferable.
In the present invention, the support layer is not particularly limited, and examples thereof include silicone, polyurethane, polyolefin, styrene-butadiene block polymer and polytetrafluoroethylene alone or as at least one component, and a silicone membrane is particularly preferable. It is preferably used and molded into a porous body.
【００１１】本発明において支持層は創傷部接触層もし
くは創傷面の水分調整、および創傷部接触層を補強する
作用を有する。本発明において繊維状の補強材は、創傷
部接触層および／または支持層に含まれていれば良く。
また、繊維状の補強材は創傷部接触層に含まれる部分と
支持層に含まれる部分とは一体化されていない、つまり
別体として各層に含まれていることが好ましい。つま
り、別体であること及び支持層が補強されていること
で、術後に支持層を容易に剥離できる。In the present invention, the support layer has a function of adjusting the water content of the wound contact layer or the wound surface and reinforcing the wound contact layer. In the present invention, the fibrous reinforcing material may be contained in the wound contact layer and / or the support layer.
Further, it is preferable that the fibrous reinforcing material is not integrated with the portion included in the wound contact layer and the portion included in the support layer, that is, is included in each layer as a separate body. That is, the support layer can be easily peeled off after the operation because it is a separate body and the support layer is reinforced.
【００１２】また、支持層が補強されていることで、創
面固定時に縫合をする際に容易に作業でき、また創面か
らの剥がれなどが少なくなる。さらに、創傷部接触層が
補強されていることで、外部からの圧迫による創傷部接
触層の変形や創面からの剥離を防ぎ、またスポンジ構造
の変形による細胞侵入性の低下が防止できる。また、補
強材により使用時に適度な剛性を持たせることにより、
貼付するときのヨレや剥がれを防止できる。Further, since the support layer is reinforced, the work can be easily performed when suturing when fixing the wound surface, and the peeling from the wound surface is reduced. Further, since the wound contact layer is reinforced, it is possible to prevent deformation of the wound contact layer due to external pressure and peeling from the wound surface, and it is possible to prevent deterioration of cell penetration due to deformation of the sponge structure. In addition, by giving a suitable rigidity when using the reinforcing material,
It can prevent twisting and peeling when sticking.
【００１３】本発明において補強材の「繊維状」とは、
織布、不織布、編布、メッシュ状やこれらの組み合わせ
た物などが挙げられ、特に限定しないが、強度を保持
し、縫合しやすくするため織布もしくは編布が望まし
い。また、薄いシート状や厚いスポンジ状に任意に調整
して用いる。本発明において繊維状の補強材の材質とし
ては、生体に対し異物性の少ないものであれば特に限定
されず、ポリエステル、ポリウレタン、ナイロン、テト
ロン、ポリオレフィンなどの合成高分子、もしくは絹、
綿、麻、キチンなどの天然由来物質が挙げられる。In the present invention, the "fibrous" reinforcing material means
Examples of the material include woven cloth, non-woven cloth, knitted cloth, mesh, and combinations thereof. However, woven cloth or knitted cloth is preferable in order to maintain strength and facilitate sewing. Also, it is used by arbitrarily adjusting it into a thin sheet shape or a thick sponge shape. The material of the fibrous reinforcing material in the present invention is not particularly limited as long as it has little foreign matter to the living body, and polyester, polyurethane, nylon, tetron, synthetic polymers such as polyolefin, or silk,
Examples include naturally occurring substances such as cotton, hemp, and chitin.
【００１４】本発明の創傷被覆材において、創傷面の治
癒促進を目的として、生理活性物質が含有されていても
良く、一般に血管新生因子、血小板由来増殖因子、線維
芽細胞増殖因子、内皮細胞増殖因子、トランスフォーミ
ング増殖因子などとして知られているものや、ヘパリン
などが使用できる。The wound dressing of the present invention may contain a physiologically active substance for the purpose of promoting healing of the wound surface, and is generally an angiogenic factor, platelet-derived growth factor, fibroblast growth factor, endothelial cell growth. Factors known as transforming growth factor, and heparin can be used.
【００１５】本発明の創傷被覆材において、創傷面より
滲出液の流出が多く創傷被覆材が浮いてしまい、治癒を
遅らせる可能性がある場合は、支持層の創傷部接触層と
接していない面（表面）から創傷部接触層の創傷と接触
する面（底面）に連通したドレイン孔を開けることによ
り、創面への密着性を向上させることができる。前記ド
レイン孔の内径は滲出液の量によって変化させるべきも
のであるが、貼付期間と滲出液の流出期間及び量を考え
ると０.５〜３mmの範囲が好ましい。In the wound dressing of the present invention, when the exudate flows out more than the wound surface and the wound dressing floats and healing may be delayed, the surface of the support layer which is not in contact with the wound contact layer. Adhesion to the wound surface can be improved by forming a drain hole that communicates from the (surface) to the surface of the wound contact layer that contacts the wound (bottom surface). The inner diameter of the drain hole should be changed depending on the amount of exudate, but it is preferably in the range of 0.5 to 3 mm considering the application period and the outflow period and amount of exudate.
【００１６】本発明の創傷被覆材の実施形態の一例とし
ては、線維化アテロコラーゲンとヘリックス含量が０〜
８０％である変性コラーゲンとからなるマトリックス
と、支持層の２層構造からなり、前記コラーゲンマトリ
ックスと支持層のどちらか一方もしくは両方に繊維状の
補強材により補強された構造を持ち、支持層のコラーゲ
ンマトリックスと接していない面からコラーゲンマトリ
ックスの創傷接触面に連通するドレイン孔が設けられて
いるものが挙げられる。As an example of the embodiment of the wound dressing of the present invention, the fibrotic atelocollagen and the helix content are 0 to
It has a two-layer structure of a matrix composed of 80% denatured collagen and a support layer, and has a structure in which one or both of the collagen matrix and the support layer is reinforced by a fibrous reinforcing material. An example is a drain hole that communicates with the wound contact surface of the collagen matrix from the surface not in contact with the collagen matrix.
【００１７】[0017]
【実施例】以下に実施例を示して本発明をさらに詳細に
説明する。 （実施例１）コラーゲンマトリックス層の作製 アテロコラーゲン（高研株式会社製）を４℃下でpH３の
塩酸溶液に溶解し、０.２〜０.３％の溶液に調整した。
この溶液を、０.２μmのフィルターで濾過滅菌し、pH
７.４のリン酸緩衝液を加えて、最終リン酸濃度が３０m
Mリン酸ナトリウム、１００mM塩化ナトリウムであり、
コラーゲン濃度が０.１〜０.１５％となるように調整し
た。また、生理活性物質としてコラーゲン量に対し０.
５％となるようにヘパリンを添加した。この溶液を３７
℃で３時間以上放置し、コラーゲンを線維状態にした。
線維は遠心分離機により３％程度に濃縮した。熱変性コ
ラーゲンは上記の滅菌後のコラーゲン溶液を用い、６０
℃で３０分以上変性させ、線維コラーゲンの１０％とと
なるように加え、線維化アテロコラーゲンと熱変性アテ
ロコラーゲンの混合液を得た。この混合液をプラスチッ
ク製シャーレに流し込み、−４０℃以下で凍結して乾燥
させスポンジ形状のマトリックスを得た。The present invention will be described in more detail with reference to the following examples. (Example 1) Preparation of collagen matrix layer Atelocollagen (manufactured by Koken Co., Ltd.) was dissolved in a hydrochloric acid solution having a pH of 3 at 4 [deg.] C. to prepare a 0.2-0.3% solution.
The solution is sterilized by filtration with a 0.2 μm filter to obtain pH.
7.4 phosphate buffer was added to give a final phosphate concentration of 30 m
M sodium phosphate, 100 mM sodium chloride,
The collagen concentration was adjusted to be 0.1 to 0.15%. In addition, the amount of collagen as a physiologically active substance is 0.
Heparin was added to be 5%. Add this solution to 37
The collagen was made into a fibrous state by leaving it for 3 hours or more at ℃.
The fiber was concentrated to about 3% by a centrifuge. As the heat-denatured collagen, the above-mentioned sterilized collagen solution is used.
The mixture was denatured at 0 ° C. for 30 minutes or more and added so as to be 10% of the fibrillar collagen to obtain a mixed solution of fibrillated atelocollagen and heat-denatured atelocollagen. This mixed solution was poured into a plastic petri dish, frozen at -40 ° C or lower, and dried to obtain a sponge-shaped matrix.
【００１８】繊維状の補強材と支持層との複合化 メディカルグレード サイラスティクＴｙｐｅＡシリコ
ーンをヘキサンで６７％となるように希釈し、溶解す
る。この溶液をテフロン板上に流延し、精密被覆用具
（アプリケーター）で３００μmに伸ばし、この上にポ
リエステル製織布（繊維厚１００μm、目付け７０ｇ/cm
2）をのせ、さらにその上に上記のコラーゲンマトリ
ックスをのせて接着した。この複合化膜は６０℃で３時
間以上乾燥硬化させた。最後に、０.０５トール以下の
真空下、１１０℃以上で２時間以上熱架橋を施し本発明
の創傷被覆材を得た。 A composite medical grade silastic type A silicone comprising a fibrous reinforcing material and a support layer is diluted with hexane to a concentration of 67% and dissolved. This solution was cast on a Teflon plate, stretched to 300 μm with a precision coating tool (applicator), and woven on polyester (fiber thickness 100 μm, basis weight 70 g / cm 2).
2 ) was placed, and the collagen matrix described above was further placed thereon and adhered. This composite film was dried and cured at 60 ° C. for 3 hours or more. Finally, heat-crosslinking was performed at 110 ° C. or higher for 2 hours or more under a vacuum of 0.05 Torr or less to obtain a wound dressing of the present invention.
【００１９】縫合強度の測定 上記で得られた創傷被覆材および比較として線維状の
補強材のない創傷被覆材を、周囲から２mm程度の深さ針
かけし、６−０の角針糸付き縫合糸で結糸縫合した。こ
の縫合糸をフォースゲージに接続し、縫合糸がはずれる
まで引っ張り、縫合強度を測定した。繊維補強創傷被覆
材では２８７ｇ（ＳＤ＝２９.９、ｎ＝４）および補強
なし創傷被覆材では１６０ｇ（ＳＤ＝１４、ｎ＝４）と
なり有為に強度の向上が見られた。 Measurement of suture strength The wound dressing material obtained above and a wound dressing material without fibrous reinforcing material as a comparison are pierced with a depth needle of about 2 mm from the surroundings, and 6-0 suture with square needle thread A suture was sutured with a thread. The suture thread was connected to a force gauge and pulled until the suture thread came off, and the suture strength was measured. The fiber-reinforced wound dressing showed 287 g (SD = 29.9, n = 4) and the unreinforced wound dressing had 160 g (SD = 14, n = 4), showing a significant improvement in strength.
【００２０】動物実験 上記で得られた創傷被覆材をラット背部全層欠損層へ
貼付し試験した。Ｗｉｓｔａｒ−ＫＹ系のラット（２０
０ｇ程度）をネンブタール麻酔下で剃毛し、イソジン消
毒した背部に皮下皮筋を残した２cm角の全層欠損層を作
製し、止血した後繊維入りの被覆材と繊維のないシリコ
ーン支持層のみの被覆材を貼付した。シリコーン層辺縁
を縫合糸で１６カ所結糸固定した。その上にメロリン
（Ｓ＆Ｎ社製）をのせ、エラスチコンテープで圧迫固定
した。移植１、２週で経時的に観察し、病理組織学的に
評価した。繊維入りの被覆材は１、２週とも良好な形状
保護性と細胞侵入を示して、良好な治癒を示していたの
に対し、繊維なしでは、短期でシリコーン膜の剥がれに
よる乾燥、縫合の糸はずれ、圧迫変形による細胞侵入性
の遅れがみられた。 Animal Experiment The wound dressing material obtained above was applied to a rat back full-thickness defect layer and tested. Wistar-KY rat (20
Approximately 0 g) was shaved under Nembutal anesthesia, and a 2 cm square full-thickness defect layer with subcutaneous skin muscle on the back disinfected with isodine was prepared. The covering material was applied. The edges of the silicone layer were fixed with sutures at 16 positions. Merolin (manufactured by S & N Co.) was placed on it and pressed and fixed with an elastic tape. It was observed over time at 1 and 2 weeks after transplantation and evaluated histopathologically. The fiber-containing dressing showed good shape protection and cell invasion for one or two weeks, and showed good healing, whereas without fiber, drying and suture thread due to peeling of the silicone film in a short period of time. There was a delay in cell invasion due to compression and deformation.
【００２１】（実施例２）実施例１−で作製した濃縮
（３％）線維化コラーゲンと熱変性コラーゲンの混合物
（９：１）をポリエステル製織布（繊維厚１００μm、
目付け７０ｇ/cm2）を広げたプラスチックシャーレに流
し込み、−４０℃以下で凍結させ、スポンジ状マトリッ
クスを得た。得られたコラーゲンマトリックスを実施例
１−と同様の手法を用いて、本発明の創傷被覆材を得
た。また、本実施例の創傷被覆材は実施例１と同様の縫
合強度の測定結果及び動物実験結果が得られた。Example 2 A mixture (9: 1) of concentrated (3%) fibrillated collagen and heat-denatured collagen prepared in Example 1 was used as a polyester woven cloth (fiber thickness 100 μm,
A basis weight of 70 g / cm 2 ) was poured into a spread plastic petri dish and frozen at -40 ° C or lower to obtain a sponge-like matrix. The obtained collagen matrix was used in the same manner as in Example 1 to obtain the wound dressing of the present invention. In addition, the wound dressing material of this example provided the same measurement results of suture strength and animal experiment results as in Example 1.
【００２２】[0022]
【発明の効果】本発明により、創傷部接触層とその上に
重層された支持層からなり、前記創傷部接触層は、線維
化アテロコラーゲンとヘリックス含量が０〜８０％であ
る変性コラーゲンとからなるマトリックスからなり、前
記支持層もしくはマトリックス層のどちらかもしくは両
方にかかるように繊維状の補強材により補強された創傷
被覆材が得られる。According to the present invention, it comprises a wound contact layer and a support layer laminated thereon, and the wound contact layer comprises fibrotic atelocollagen and denatured collagen having a helix content of 0 to 80%. A wound dressing composed of a matrix and reinforced with a fibrous reinforcement so as to cover either or both of the support layer and the matrix layer is obtained.
【００２３】本発明の創傷被覆材は、創傷、熱傷、褥瘡
等により組織が損傷を受けた場合に、損傷面に適用さ
れ、創面を保護し、疼痛を緩和し、細菌の感染を防止す
る。本発明の創傷被覆材は、創傷接触面で細胞侵入性を
有し、早期に線維芽細胞、毛細血管の侵入し、真皮様組
織を構築するため創傷の治癒が促進される。このとき補
強材により補強されているため、細胞の侵入が阻害され
ず、より良好な治癒が得られる。更に、移植して一定期
間たった後、上部の支持層を剥し、自家の分層植皮を行
うことにより、よりよい分層植皮の生着と治癒が得られ
る。The wound dressing of the present invention is applied to a damaged surface when a tissue is damaged by a wound, a burn, a pressure ulcer, etc. to protect the wound surface, relieve pain, and prevent bacterial infection. The wound dressing of the present invention has cell-penetrating properties on the wound contact surface, infiltrates fibroblasts and capillaries at an early stage, and constructs a dermis-like tissue to promote wound healing. At this time, since it is reinforced by the reinforcing material, cell invasion is not hindered, and better healing can be obtained. Further, after a certain period of time after transplantation, the upper support layer is peeled off and autologous split-thickness skin grafting is performed, whereby better survival and healing of split-thickness skin graft can be obtained.
Claims (1)
からなる創傷被覆材において、前記創傷部接触層および
／または支持層が繊維状の補強材により補強された創傷
被覆材。1. A wound dressing comprising a wound contact layer and a support layer overlaid thereon, wherein the wound contact layer and / or the support layer is reinforced by a fibrous reinforcing material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32415393A JP3503974B2 (en) | 1993-12-22 | 1993-12-22 | Wound dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32415393A JP3503974B2 (en) | 1993-12-22 | 1993-12-22 | Wound dressing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07178131A true JPH07178131A (en) | 1995-07-18 |
| JP3503974B2 JP3503974B2 (en) | 2004-03-08 |
Family
ID=18162725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32415393A Expired - Fee Related JP3503974B2 (en) | 1993-12-22 | 1993-12-22 | Wound dressing |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3503974B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100319261B1 (en) * | 1999-09-18 | 2002-01-05 | 허승욱 | Orthopedic splint and brace |
| US6977231B1 (en) | 1999-01-21 | 2005-12-20 | Nipro Corporation | Suturable adhesion-preventing membrane |
| CN110152048A (en) * | 2019-05-13 | 2019-08-23 | 浙江惠龙医疗科技股份有限公司 | One kind having anti-scar regeneration function medical dressing and preparation method thereof |
| US12076964B1 (en) | 2023-07-06 | 2024-09-03 | Saikyo Biotech Co., Ltd. | Hydrophilized expanded PTFE and method of hydrophilizing expanded PTFE |
-
1993
- 1993-12-22 JP JP32415393A patent/JP3503974B2/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977231B1 (en) | 1999-01-21 | 2005-12-20 | Nipro Corporation | Suturable adhesion-preventing membrane |
| KR100319261B1 (en) * | 1999-09-18 | 2002-01-05 | 허승욱 | Orthopedic splint and brace |
| CN110152048A (en) * | 2019-05-13 | 2019-08-23 | 浙江惠龙医疗科技股份有限公司 | One kind having anti-scar regeneration function medical dressing and preparation method thereof |
| US12076964B1 (en) | 2023-07-06 | 2024-09-03 | Saikyo Biotech Co., Ltd. | Hydrophilized expanded PTFE and method of hydrophilizing expanded PTFE |
| WO2025009150A1 (en) * | 2023-07-06 | 2025-01-09 | 西京バイオテック株式会社 | Hydrophilic eptfe sheet and method for making eptfe sheet hydrophilic |
| JP7636832B1 (en) * | 2023-07-06 | 2025-02-27 | 西京バイオテック株式会社 | Hydrophilic ePTFE sheet and method for hydrophilizing ePTFE sheet |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3503974B2 (en) | 2004-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ng et al. | In vivo evaluation of an ultra-thin polycaprolactone film as a wound dressing | |
| EP0265906B1 (en) | Wound dressing | |
| EP1259269B1 (en) | Agent for the treatment of wounds | |
| KR100860896B1 (en) | Bioabsorbable Wound Dressing | |
| Chvapil | Considerations on manufacturing principles of a synthetic burn dressing: a review | |
| US5263983A (en) | Medical material and prosthetic skin in which cells can invade | |
| US5350583A (en) | Cell-penetrable medical material and artificial skin | |
| JP3476631B2 (en) | Medical material composed of human-derived natural collagen membrane | |
| Basu et al. | Wound healing materials–a perspective for skin tissue engineering | |
| JP5160081B2 (en) | Wound dressings containing oxidized cellulose and human recombinant collagen | |
| US20030133967A1 (en) | Multilayer collagen matrix for tissue reconstruction | |
| JP3726280B2 (en) | Medical collagen membrane | |
| JPWO2002045767A1 (en) | Tissue regeneration base material, transplant material, and methods for producing them | |
| JP3503974B2 (en) | Wound dressing | |
| WO1989008466A1 (en) | Medical material permitting cells to enter thereinto and artificial skin | |
| Mao et al. | Nonwoven wound dressings | |
| JPH05184661A (en) | Artificial skin | |
| JP2987464B2 (en) | Artificial skin | |
| JPH05192363A (en) | Wound covering material | |
| JP2852954B2 (en) | Artificial skin and method for producing the same | |
| JPH08196618A (en) | Cell invasive collagen formulation, artificial skin and their manufacture | |
| JPH0481466B2 (en) | ||
| Doillon | Skin replacement using collagen extracted from bovine hide | |
| JP2001017532A (en) | Wound dressing | |
| JPH05285210A (en) | Artificial skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20031202 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20031209 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081219 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091219 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101219 Year of fee payment: 7 |
|
| LAPS | Cancellation because of no payment of annual fees |